Eli Lilly and : Submission of Matters to a Vote of Security Holders
May 05, 2021 at 07:01 am EDT
Share
Submission of Matters to a Vote of Security Holders
Eli Lilly and Company (the 'Company') held its annual meeting of shareholders on May 3, 2021 (the '2021 Annual Meeting'). Voting results for each matter submitted to a vote at the 2021 Annual Meeting are provided below.
a)
The five nominees for director were elected to serve three-year terms ending at the Company's annual meeting of shareholders in 2024, as follows:
Nominee
For
Against
Abstain
Broker Nonvote
Katherine Baicker, Ph.D.
786,556,365
3,971,888
683,224
78,905,324
J. Erik Fyrwald
735,805,887
54,570,383
835,207
78,905,324
Jamere Jackson
699,430,362
90,868,049
913,066
78,905,324
Gabrielle Sulzberger
784,273,387
6,013,712
924,378
78,905,324
Jackson P. Tai
614,200,469
168,883,624
8,127,384
78,905,324
b)
By the following vote, the shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers:
For:
755,296,772
Against:
34,051,860
Abstain:
1,862,845
Broker Nonvote:
78,905,324
c)
The appointment of Ernst & Young as the Company's independent auditor for 2021 was ratified by the following shareholder vote:
For:
835,119,026
Against:
34,286,470
Abstain:
711,305
d)
The proposal to amend the Company's Articles of Incorporation to eliminate the classified board structure did not receive the required vote of 80% of outstanding shares. The shareholders voted as follows:
For:
672,397,991
Against:
117,428,685
Abstain:
1,384,801
Broker Nonvote:
78,905,324
e)
The proposal to amend the Company's Articles of Incorporation to eliminate supermajority voting provisions did not receive the required vote of 80% of outstanding shares. The shareholders voted as follows:
For:
671,655,729
Against:
118,200,383
Abstain:
1,355,365
Broker Nonvote:
78,905,324
f)
By the following vote, a shareholder proposal requesting to disclose direct and indirect lobbying activities and expenditures was not approved:
For:
380,312,826
Against:
408,488,220
Abstain:
2,410,431
Broker Nonvote:
78,905,324
g)
By the following vote, a shareholder proposal requesting to amend the bylaws to require an independent board chair was not approved:
For:
286,294,523
Against:
503,034,078
Abstain:
1,882,876
Broker Nonvote:
78,905,324
h)
By the following vote, a shareholder proposal requesting the implementation of a bonus deferral policy was not approved:
For:
246,751,698
Against:
542,574,049
Abstain:
1,885,730
Broker Nonvote:
78,905,324
i)
By the following vote, a shareholder proposal requesting to disclose clawbacks on executive incentive compensation due to misconduct was not approved:
For:
322,735,091
Against:
466,847,278
Abstain:
1,629,108
Broker Nonvote:
78,905,324
As of February 22, 2021, the record date of the 2021 Annual Meeting, 958,992,159 shares of common stock were issued and outstanding.
Attachments
Original document
Permalink
Disclaimer
Eli Lilly and Company published this content on 05 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 May 2021 11:00:05 UTC.
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
ELI LILLY AND COMPANY 
